| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Proceeds from issuance of convertible notes | - | 0 |
| Net cash provided by financing activities | 7,411 | 5,514 |
| Effect of exchange rates on cash | 1 | 4 |
| Net change in cash | -115 | 112 |
| Cash and cash equivalents at beginning of period | 2,659 | - |
| Cash and cash equivalents at end of period | 2,544 | - |
Akari Therapeutics Plc (AKTX)
Akari Therapeutics Plc (AKTX)